TinaHashiRN said:Dr.AddMedPHL said: ...but the FDA says semaglutide...
All correct, with the caveat that "maintenance dose" in the literature almost always means the top studied dose. Lower maintenance doses are widely used and thinly evidenced, which is worth knowing before you cite anything as established.
From the other side of the consultation, briefly. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.
Worth separating that from the maintenance and discontinuation question, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
Dr.PeteFamMed said:If two explanations both fit, the useful question is which one predicts something the other does not.
This is my experience too, for whatever a second data point is worth.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemDr.PeteFamMed said:If two explanations both fit, the useful question is which one predicts something the other does not.
Adding the part of the answer the thread has not reached. Extending the interval and reducing the dose are pharmacologically different. Reducing the dose lowers the whole exposure curve evenly; extending the interval keeps the peak and drops the trough. Since the appetite effect tracks the trough, interval extension tends to give you good days and bad days rather than a uniformly smaller effect, which most people find harder to live with.
Happy to go further on any of that.
Moderator note: the sourcing question belongs in the vendor section and has been split out. Report rather than reply if it drifts again.